Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation

被引:290
作者
Yusuf, R. Z. [1 ]
Duan, Z. [1 ]
Lamendola, D. E. [1 ]
Penson, R. T. [1 ]
Seiden, M. V. [1 ]
机构
[1] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA
关键词
paclitaxel; drug resistance; reversal of drug resistance; in vivo drug resistance assays; MDR; Pgp; beta-tubulin; cytokine;
D O I
10.2174/1568009033333754
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It has been approximately ten years since the Food and Drug Administration (FDA) approved paclitaxel for the treatment of platinum resistant epithelial ovarian carcinoma. Since the approval, the drug has found therapeutic applications in a variety of schedules and in a wide variety of epithelial malignancies. Its novel mechanism of action provided the hope that it would demonstrate anti-neoplastic activity in multidrug resistant tumor cells. Unfortunately, as with other chemotherapeutic drugs, resistance is commonly seen. Laboratory investigation has defined a wide variety of resistance mechanisms including overexpression of multidrug resistance (MDR-1) gene, molecular changes in the target molecule (beta- tubulin), changes in apoptotic regulatory and mitosis checkpoint proteins, and more recently changes in lipid composition and potentially the overexpression of interleukin 6 (IL- 6). This review describes the in vitro molecular data that define and support the various mechanisms of resistance and critically evaluates the evidence for the participation of these mechanisms in clinically relevant paclitaxel resistance. This review also explores pharmacologic attempts to modulate paclitaxel resistance, principally through inhibition of the MDR-1 drug efflux pump. Future avenues for drug resistance research and its pharmacologic manipulation in the clinic are discussed.
引用
收藏
页码:1 / 19
页数:19
相关论文
共 190 条
[1]  
Advani R, 2001, CLIN CANCER RES, V7, P1221
[2]  
Agiostratidou G, 2001, ANTICANCER RES, V21, P455
[3]   GENERATION OF A DRUG-RESISTANCE PROFILE BY QUANTITATION OF MDR-1/P-GLYCOPROTEIN IN THE CELL-LINES OF THE NATIONAL-CANCER-INSTITUTE ANTICANCER DRUG SCREEN [J].
ALVAREZ, M ;
PAULL, K ;
MONKS, A ;
HOSE, C ;
LEE, JS ;
WEINSTEIN, J ;
GREVER, M ;
BATES, S ;
FOJO, T .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (05) :2205-2214
[4]   Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells [J].
Aoudjit, F ;
Vuori, K .
ONCOGENE, 2001, 20 (36) :4995-5004
[5]  
Arts HJG, 1999, CLIN CANCER RES, V5, P2798
[6]   CHROMOSOME-17 DELETIONS AND P53 GENE-MUTATIONS IN COLORECTAL CARCINOMAS [J].
BAKER, SJ ;
FEARON, ER ;
NIGRO, JM ;
HAMILTON, SR ;
PREISINGER, AC ;
JESSUP, JM ;
VANTUINEN, P ;
LEDBETTER, DH ;
BARKER, DF ;
NAKAMURA, Y ;
WHITE, R ;
VOGELSTEIN, B .
SCIENCE, 1989, 244 (4901) :217-221
[7]  
BANERJEE A, 1992, J BIOL CHEM, V267, P5625
[8]   THE POTENTIAL OF PROTEIN-KINASE-C AS A TARGET FOR ANTICANCER TREATMENT [J].
BASU, A .
PHARMACOLOGY & THERAPEUTICS, 1993, 59 (03) :257-280
[9]   Fundamental relationships between the composition of Pluronic block copolymers and their hypersensitization effect in MDR cancer cells [J].
Batrakova, E ;
Lee, S ;
Li, S ;
Venne, A ;
Alakhov, V ;
Kabanov, A .
PHARMACEUTICAL RESEARCH, 1999, 16 (09) :1373-1379
[10]   DETECTION OF P-GLYCOPROTEIN IN OVARIAN-CANCER - A MOLECULAR MARKER ASSOCIATED WITH MULTIDRUG RESISTANCE [J].
BELL, DR ;
GERLACH, JH ;
KARTNER, N ;
BUICK, RN ;
LING, V .
JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (03) :311-315